A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine
暂无分享,去创建一个
G. Luker | J. Baker | A. Bielinska | K. Janczak | A. Chepurnov | Jeffrey J Landers | T. Chepurnova | J. Baker
[1] J. Millar,et al. [Complications of smallpox vaccination]. , 2010, [Hokenfu zasshi] The Japanese journal for public health nurse.
[2] Mario Roederer,et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses , 2007, The Journal of experimental medicine.
[3] A. Phelps,et al. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. , 2007, Vaccine.
[4] P. Sly,et al. Accelerated Antigen Sampling and Transport by Airway Mucosal Dendritic Cells following Inhalation of a Bacterial Stimulus1 , 2006, The Journal of Immunology.
[5] Andrew Pekosz,et al. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. , 2005, Virology.
[6] F. Falkner,et al. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. , 2005, Virology.
[7] K. Reimann,et al. Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus , 2005, Nature Medicine.
[8] B. Guy,et al. New adjuvants for parenteral and mucosal vaccines. , 2005, Therapie.
[9] Jan Holmgren,et al. Mucosal immunity and vaccines , 2005, Nature Medicine.
[10] G. Poland,et al. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. , 2005, Vaccine.
[11] F. Ennis,et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial , 2005, The Lancet.
[12] M. Selgelid. Bioterrorism and smallpox planning: information and voluntary vaccination , 2004, Journal of Medical Ethics.
[13] Christiana N. Fogg,et al. Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions , 2004, Journal of Virology.
[14] A. Vila,et al. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[15] M. Schwehm,et al. Smallpox: a vulnerable specter. , 2004, Epidemiology.
[16] P. Earl,et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox , 2004, Nature.
[17] R. Couch. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.
[18] Eric Gross. Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. , 2003, MMWR. Morbidity and mortality weekly report.
[19] G. Poland,et al. Smallpox vaccines: current and future. , 2003, The Journal of laboratory and clinical medicine.
[20] M. Olszewski,et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. , 2003, Vaccine.
[21] S. Hansen,et al. Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.
[22] Lihan K. Yan,et al. Improved Assay To Detect Neutralizing Antibody following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) Vaccine , 2003, Journal of Clinical Microbiology.
[23] E. Thompson,et al. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates , 2003, Virology.
[24] J. Viret,et al. Experience with registered mucosal vaccines. , 2003, Vaccine.
[25] Gary D. Luker,et al. Noninvasive Bioluminescence Imaging of Herpes Simplex Virus Type 1 Infection and Therapy in Living Mice , 2002, Journal of Virology.
[26] R. Ahmed,et al. Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope , 2002, Journal of Virology.
[27] N. Weiner,et al. Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. , 2001, International journal of pharmaceutics.
[28] N. Weiner,et al. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. , 2001, International journal of pharmaceutics.
[29] James R. Baker,et al. Prevention of Murine Influenza a Virus Pneumonitis by Surfactant Nano-Emulsions , 2000, Antiviral chemistry & chemotherapy.
[30] J. Ramírez,et al. Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.
[31] J. Whitton,et al. Activated and Memory CD8+ T Cells Can Be Distinguished by Their Cytokine Profiles and Phenotypic Markers1 , 2000, The Journal of Immunology.
[32] J. Baker,et al. A novel surfactant nanoemulsion with broad-spectrum sporicidal activity against Bacillus species. , 1999, The Journal of infectious diseases.
[33] R. Wittek,et al. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. , 1999, Virology.
[34] R. Massung,et al. PCR strategy for identification and differentiation of small pox and other orthopoxviruses , 1995, Journal of clinical microbiology.
[35] B. Moss,et al. Selection of recombinant vaccinia viruses on the basis of plaque formation. , 1995, Gene.
[36] C. Walker,et al. Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. , 1993, The Journal of general virology.
[37] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .
[38] J. Baker,et al. The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi , 2004, Mycopathologia.
[39] M. Lorenzo,et al. Construction and isolation of recombinant vaccinia virus using genetic markers. , 2004, Methods in molecular biology.
[40] J. Baker,et al. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. , 2001, Microbiological research.
[41] R. Thompson,et al. Complications of smallpox vaccination in Washington, 1968. , 1971, Northwest medicine.
[42] V. M. Tarabrina. [On complications in smallpox vaccination]. , 1961, Sovetskaia meditsina.